A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (NCT05852691)
A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, tobemstomig, in combination with nab-paclitaxel, for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC).
Who can join: Review the eligibility criteria below.
Location: Cancer Blood and Specialty Clinic — Los Alamitos, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (36 Sites)
Showing the first 25 of 36 sites.
- Cancer Blood and Specialty Clinic — Los Alamitos, California
- Memorial Sloan-Kettering Cancer Center — New York, New York
- Novant Health Presbyterain Medical Center — Charlotte, North Carolina
- Avera Cancer Institute — Sioux Falls, South Dakota
- Centro de Investigaciones Médicas y Desarrollo LC S.R.L — Buenos Aires,
- Sunshine Hospital — St Albans, Victoria
- Hospital Araujo Jorge — Goiânia, Goiás
- Hospital do Cancer de Pernambuco - HCP — Recife, Pernambuco
- Hospital de Cancer de Barretos — Barretos, São Paulo
- Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda — São Paulo, São Paulo
- Fakultni Thomayerova nemocnice — Praha 4 - Krc,
- Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH — Essen,
- Dres. Andreas Köhler und Roswitha Fuchs — Langen,
- Universitätsklinikum Ulm Am Michelsberg — Ulm,
- Komarom-Eszergom Varmegyei Szent Borbala Korhaz — Tatabánya,
- Hadassah University Hospital - Ein Kerem — Jerusaelm,
- Sheba Medical Center — Ramat Gan,
- Ospedale Provinciale Santa Maria Delle Croci — Ravenna, Emilia-Romagna
- Ospedale San Raffaele — Milan, Lombardy
- Health Pharma Professional Research — Mexico City, Mexico CITY (federal District)
- OncoMed — Mexico City, Mexico CITY (federal District)
- Centro Médico Zambrano Hellion — Monterrey, Nuevo León
- Centro de Investigacion Clinica de Oaxaca — Oaxaca City, Oaxaca
- Centro Medico Monte Carmelo — Arequipa,
- Oncosalud Sac — Lima,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.